Holen Sie sich die Stockscreener-App
8.13
12.76%
0.92
Handel nachbörslich:
8.13
Schlusskurs vom Vortag:
$7.21
Offen:
$7.62
24-Stunden-Volumen:
4.95M
Relative Volume:
1.98
Marktkapitalisierung:
$1.35B
Einnahmen:
$246.03M
Nettoeinkommen (Verlust:
$-32.00M
KGV:
-38.26
EPS:
-0.2125
Netto-Cashflow:
$-16.78M
1W Leistung:
+3.57%
1M Leistung:
+16.31%
6M Leistung:
+70.44%
1J Leistung:
+141.96%
1-Tages-Spanne:
$7.57
$8.42
1-Wochen-Bereich:
$6.884
$8.42
52-Wochen-Spanne:
$3.14
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Firmenname
Xeris Biopharma Holdings Inc
Sektor
Branche
Telefon
844-445-5704
Adresse
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Vergleichen Sie XERS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
8.13 | 1.20B | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2023-08-28 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-16 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
Xeris Biopharma expects full-year 2025 revenue above estimates - MSN
Is Xeris Biopharma Holdings Inc. stock positioned well for digital economyJuly 2025 Rallies & Reliable Entry Point Trade Alerts - ulpravda.ru
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue - BioSpace
Xeris Biopharma (XERS) Exceeds 2025 Revenue Expectations - GuruFocus
A biotech treating 700 patients is on track for a record revenue year - Stock Titan
Will Xeris Biopharma Holdings Inc. stock pay special dividendsAutomated Trading Signals & Rapid Portfolio Investment - ulpravda.ru
Xeris Biopharma director Shannon sells $176k in shares By Investing.com - Investing.com Canada
Xeris Biopharma director Shannon sells $176k in shares - Investing.com India
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Diversified Trust Co - MarketBeat
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Xeris Biopharma (NASDAQ:XERS) Trading Down 6.8%Time to Sell? - MarketBeat
Calamos Advisors LLC Makes New Investment in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday - Finviz
Is Xeris Biopharma on the Verge of a Breakthrough? - StocksToTrade
Xeris Biopharma Holdings Inc. (XERS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
XERS FinancialsIncome Statement - Quiver Quantitative
Xeris Biopharma (NASDAQ:XERS) Shares Gap UpShould You Buy? - MarketBeat
Investors Buy Large Volume of Call Options on Xeris Biopharma (NASDAQ:XERS) - MarketBeat
Jefferies reiterates Buy rating on Xeris Pharmaceuticals stock amid competitor setback By Investing.com - Investing.com Nigeria
Jefferies reiterates Buy rating on Xeris Pharmaceuticals stock amid competitor setback - Investing.com
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? - MSN
Xeris Biopharma Holdings, Inc. $XERS Shares Acquired by Voya Investment Management LLC - MarketBeat
Oppenheimer Maintains Xeris Biopharma Holdings (XERS) Outperform Recommendation - MSN
Have Xeris Biopharma Holdings Insiders Been Selling Stock? - Sahm
Will Xeris Biopharma Holdings Inc. stock benefit from sector rotationJuly 2025 Technicals & High Accuracy Buy Signal Tips - Улправда
Squarepoint Ops LLC Purchases 268,572 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma (XERS): Assessing Valuation as Investors Back Its Shift to Profitable Specialty Pharma - Sahm
EBIT per share of Xeris Biopharma Holdings, Inc. – LSE:0A8E - TradingView — Track All Markets
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Director John Johnson Sells 135,400 Shares of Xeris Biopharma Ho - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Director Sells $977,588.00 in Stock - MarketBeat
Xeris Biopharma Holdings Insider Sold Shares Worth $977,019, According to a Recent SEC Filing - marketscreener.com
Will Xeris Biopharma Holdings Inc. stock reach all time highs in 20252025 Investor Takeaways & Free Long-Term Investment Growth Plans - DonanımHaber
How Xeris Biopharma’s Shift Toward Profitability and Pipeline Maturity Will Impact Xeris (XERS) Investors - Sahm
Is Xeris Biopharma Holdings Inc. stock a contrarian buyJuly 2025 Selloffs & Safe Entry Point Alerts - Улправда
Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory - Finviz
Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade) - Seeking Alpha
Insider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells 15,000 Shares of Stock - MarketBeat
Insider Sell: Barbara-jean Bormann-kennedy Sells 15,000 Shares o - GuruFocus
Xeris Biopharma (XERS) director reports 15,000-share stock sale - Stock Titan
Walleye Capital LLC Sells 448,444 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Jump Financial LLC Raises Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
561,700 Shares in Xeris Biopharma Holdings, Inc. $XERS Bought by Norges Bank - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Coverage Initiated at Barclays - MarketBeat
Barclays Initiates Coverage on Xeris Biopharma Holdings (XERS) w - GuruFocus
Barclays Initiates Xeris Biopharma Holdings at Overweight With $9 Price Target - marketscreener.com
Xeris Biopharma (XERS): Valuation Check After USPTO Notice of Allowance for Weekly Levothyroxine XP-8121 Patent - Sahm
Xeris Biopharma’s (XERS) Positioning Strengthens After Reaching Product Pipeline Milestone - Insider Monkey
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xeris Biopharma Holdings Inc-Aktie (XERS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shannon John Patrick Jr | See Remarks |
Jan 05 '26 |
Sale |
7.08 |
24,907 |
176,257 |
2,705,346 |
| Hecht Beth | See Remarks |
Jan 02 '26 |
Sale |
7.43 |
16,667 |
123,776 |
1,308,103 |
0.80%
4.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):